Elaine V. Jones, Ph.D. is currently a Vice President, Venture Capital, at Pfizer Venture Investments. Since joining the team in 2008, she is responsible for making and managing venture investments for Pfizer and currently oversees the PVI investments in Autifony Therapeutics Ltd., Blade Therapeutics, eFFECTOR Therapeutics, Mersana Therapeutics, MISSION Therapeutics, Nimbus Therapeutics LLC, Second Genome, and Storm Therapeutics. Elaine brings 18 years of venture capital experience and a strong background in research and product assessment, built on her significant experience in pharmaceutical drug discovery and business development to the PVI team.

Dr. Jones also manages Pfizer’s R&D Innovate initiative which invests in early stage biotechnology companies that are closely aligned with Pfizer’s R&D strategy. In this role, she serves on the boards of Arrakis, Jnana, and NextCure.

Prior to joining Pfizer, Dr. Jones was a General Partner with the venture fund, EuclidSR Partners. There, she was responsible for the fund’s investments in Acurian, Fluidigm, InnaPhase and Targacept.

Dr. Jones began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund, where she managed investments including Adolor, Avantium, Nucleonics, Scynexis and Vicuron. Previously, she served as Director of Scientific Licensing for SmithKline Beecham and was a research scientist in SmithKline Beecham Pharmaceutical R&D.

Dr. Jones is a graduate of Juniata College and received her Ph.D. in Microbiology from the University of Pittsburgh.